CDC73

Summary

CDC73 (cell division cycle 73, HGNC:16783) is a protein-coding gene on chromosome 1q31.2, encoding Parafibromin (Q6P1J9). Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. It is a common-essential gene (DepMap: required in 98.7% of cancer cell lines) and haploinsufficient (ClinGen: sufficient evidence).

This gene encodes a tumor suppressor that is involved in transcriptional and post-transcriptional control pathways. The protein is a component of the the PAF protein complex, which associates with the RNA polymerase II subunit POLR2A and with a histone methyltransferase complex. This protein appears to facilitate the association of 3’ mRNA processing factors with actively-transcribed chromatin. Mutations in this gene have been linked to hyperparathyroidism-jaw tumor syndrome, familial isolated hyperparathyroidism, and parathyroid carcinoma.

Source: NCBI Gene 79577 — RefSeq curated summary.

At a glance

• Gene–disease (curated): hyperparathyroidism 2 with jaw tumors (Definitive, ClinGen) — +3 more curated relationships
• GWAS associations: 7
• Clinical variants (ClinVar): 1,986 total — 141 pathogenic, 31 likely-pathogenic
• Phenotypes (HPO): 51
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• Cancer driver (intOGen): activating (oncogene-like) across 1 cancer types
• Cancer dependency (DepMap): dependent in 98.7% of screened cell lines (common-essential)
• Dosage sensitivity (ClinGen): haploinsufficiency sufficient evidence, triplosensitivity no evidence
• MANE Select transcript: NM_024529

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16783
Approved symbol	CDC73
Name	cell division cycle 73
Location	1q31.2
Locus type	gene with protein product
Status	Approved
Aliases	parafibromin, FIHP
Ensembl gene	ENSG00000134371
Ensembl biotype	protein_coding
OMIM	607393
Entrez	79577

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 9 protein_coding, 7 protein_coding_CDS_not_defined, 5 nonsense_mediated_decay

ENST00000367435, ENST00000477868, ENST00000482484, ENST00000635846, ENST00000643006, ENST00000643784, ENST00000647662, ENST00000648071, ENST00000649606, ENST00000649613, ENST00000649706, ENST00000649895, ENST00000650197, ENST00000713651, ENST00000713652, ENST00000864170, ENST00000864171, ENST00000916534, ENST00000958309, ENST00000958310, ENST00000958311

RefSeq mRNA: 1 — MANE Select: NM_024529 NM_024529

CCDS: CCDS1382

Canonical transcript exons

ENST00000367435 — 17 exons

Exon	Start	End
ENSE00000914553	193147867	193147965
ENSE00000914555	193150304	193150382
ENSE00000995910	193141850	193142066
ENSE00002208937	193203795	193203852
ENSE00002267887	193152380	193152444
ENSE00002270543	193212065	193212100
ENSE00002310203	193236256	193236356
ENSE00002421874	193212390	193212477
ENSE00003497095	193125112	193125217
ENSE00003508580	193135537	193135589
ENSE00003613711	193130174	193130243
ENSE00003639503	193249730	193249871
ENSE00003641635	193135391	193135453
ENSE00003643291	193138085	193138173
ENSE00003837931	193122031	193122331
ENSE00004020585	193232993	193233154
ENSE00004020587	193250676	193254815

Expression profiles

Bgee: expression breadth ubiquitous, 271 present calls, max score 95.14.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 50.9332 / max 728.8657, expressed in 1821 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
7480	39.6076	1819
7481	8.1879	1678
7482	2.0776	1122
7483	0.5273	231
7479	0.3208	148
7478	0.2120	98

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	95.14	gold quality
sural nerve	UBERON:0015488	94.85	gold quality
colonic epithelium	UBERON:0000397	92.79	gold quality
tendon	UBERON:0000043	91.68	gold quality
monocyte	CL:0000576	91.35	gold quality
adrenal tissue	UBERON:0018303	91.32	gold quality
ventricular zone	UBERON:0003053	91.00	gold quality
mononuclear cell	CL:0000842	90.97	gold quality
islet of Langerhans	UBERON:0000006	90.96	gold quality
stromal cell of endometrium	CL:0002255	90.76	gold quality
leukocyte	CL:0000738	90.57	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	88.47	gold quality
cauda epididymis	UBERON:0004360	88.40	gold quality
heart right ventricle	UBERON:0002080	88.32	gold quality
popliteal artery	UBERON:0002250	88.17	gold quality
tibial artery	UBERON:0007610	88.15	gold quality
amniotic fluid	UBERON:0000173	87.94	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.88	gold quality
corpus callosum	UBERON:0002336	87.87	gold quality
medial globus pallidus	UBERON:0002477	87.35	gold quality
gall bladder	UBERON:0002110	87.32	gold quality
tonsil	UBERON:0002372	87.05	gold quality
rectum	UBERON:0001052	86.98	gold quality
cartilage tissue	UBERON:0002418	86.70	gold quality
bone marrow	UBERON:0002371	86.61	gold quality
choroid plexus epithelium	UBERON:0003911	86.61	gold quality
gastrocnemius	UBERON:0001388	86.60	gold quality
aorta	UBERON:0000947	86.54	gold quality
muscle of leg	UBERON:0001383	86.43	gold quality
ganglionic eminence	UBERON:0004023	86.28	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.63

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
MYC	Repression

Upstream regulators (CollecTRI, top): HMGA2, MYC, WT1

miRNA regulators (miRDB)

214 targeting CDC73, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-4531	99.99	69.70	3181

Functional genomics

ClinGen dosage: haploinsufficiency 3 (sufficient evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 98.7% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 40)

• This gene is now identified as associated with the hyperparathyroidism-jaw tumor syndrome. (PMID:12434154)
• It is hypothesised that HRPT2 mutation is an early event that may lead to parathyroid malignancy and suggest intragenic mutation of HRPT2 as a marker of malignant potential in both familial and sporadic parathyroid tumours. (PMID:12960210)
• among 32 familial isolated hyperparathyroidism families, only a single one was found to have a mutation in parafibromin (HRPT2) gene (PMID:14715834)
• genotype phenotype analysis in familial isolated hyperparathyroidism (PMID:14985373)
• mutations in the HRPT2 gene are likely to be associated with parathyroid tumourigenesis; DNA mutational analysis in familial isolated hyperparathyroidism (PMID:14985403)
• Missense Mutation in HRPT2 is associated with Hyperparathyroidism Jaw-tumor syndrome. (PMID:15046050)
• Mutations in HRPT2 is associated with Hyperparathyroidism Jaw-tumor syndrome. (PMID:15046094)
• Mutations in HRPT2 is associated with Hyperparathyroidism Jaw-tumor syndrome. (PMID:15046098)
• Mutations in HRPT2 is associated with Hyperparathyroidism Jaw-tumor syndrome. (PMID:15046102)
• Mutations in HRPT2 is associated with Hyperparathyroidism Jaw-tumor syndrome. (PMID:15046105)
• Mutations in HRPT2 is associated with Hyperparathyroidism Jaw-tumor syndrome. (PMID:15046107)
• Mutations in HRPT2 is associated with Hyperparathyroidism Jaw-tumor syndrome. (PMID:15046109)
• Patients shared common haplotype of seven markers spannning approximately 12.5-cM region, flanked centromerically by D1S202 and telomerically by D1S306. A 2-bp (TG or GT) frameshift deletion in exon 8, which predicts a truncated parafibromin protein. (PMID:15070940)
• Human parafibromin is a nucleocytoplasmic tumor suppressor protein which regulates cyclin D1/PRAD1 expression. (PMID:15580289)
• Mutation of HRPT2 is associated with the formation of parathyroid tumors in hyperparathyroidism-jaw tumor syndrome. (PMID:15613436)
• By purifying cellular parafibromin and characterizing its associated proteins, a human counterpart to the yeast Paf1 complex including homologs of Leo1, Paf1, and Ctr9, has been described. (PMID:15632063)
• findings link the tumor suppressor parafibromin to the transcription elongation and RNA processing pathway as a PAF1 complex- and RNA polymerase II-bound protein. (PMID:15923622)
• HRPT2 inactivation is not an important participant in the pathogenesis of typical parathyroid adenomas. (PMID:15956079)
• A non-consensus (non-canonical) donor splice site within exon 1 of the HRPT2 gene is associated with familial isolated primary hyperparathyroidism (FIHP). (PMID:16061557)
• specific HRPT2 mutations identified in HPT-JT or sporadic parathyroid carcinoma predicted to truncate parafibromin upstream of or within this NLS disrupt nuclear localization (PMID:16116486)
• mutation in exon 1 (nt 20AGGACG –> GGGAG) is predicted to inactivate the parafibromin protein through protein truncation and premature termination of translation (PMID:16448924)
• Data show that Drosophila Hyrax and its human ortholog, Parafibromin, are required for nuclear transduction of the Wnt/Wg signal and bind directly to the C-terminal region of beta-catenin/Armadillo. (PMID:16630820)
• The presented data suggest that in the majority of benign parathyroid tumours the expression of parafibromin remains unaltered, while the loss of parafibromin expression is strongly indicative of gene inactivation through mutation of the HRPT2 gene. (PMID:16728578)
• parafibromin has a critical role in cell growth, and mutations in HRPT2 can directly inhibit this role (PMID:16989776)
• renal cancer-associated mutations in parafibromin occur in the absence of von Hippel-Lindau mutation (PMID:17130827)
• The molecular basis for HPT has been further elucidated by teh detection of inactivating germline mutations in the CaSR gene in familial hypocalciuric hypercalcemia syndrome and in the HRPT-2 genes in the familial forms of HPT. (PMID:17138574)
• These experiments identify for the first time a proapoptotic activity of endogenous parafibromin likely to be important in its role as a tumor suppressor and show a functional role for the NLS of parafibromin in this activity. (PMID:17314275)
• Acts as a positive regulator of cell growth similar to an oncoprotein in the presence of Simian virus 40 large T antigen. (PMID:17404568)
• These results suggest that not only HRPT2 but also MEN1 mutations may play a role in sporadic parathyroid cancer formation. (PMID:17555500)
• Three identified NoLSs play only a minor role in nuclear localization, but are critical for the nucleolar localization of parafibromin. (PMID:17923126)
• Downregulated parafibromin expression possibly contributed to pathogenesis, growth, invasion and metastasis of gastric carcinomas. (PMID:18080135)
• loss of HRPT2 gene expression is strongly associated with parathyroid carcinomas. (PMID:18217513)
• inactivating mutations and/or allelic loss of the HRPT2 gene may not play a major role in parathyroid carcinogenesis in secondary HPT due to CKD (PMID:18338208)
• germline mutations with familial hyperparathyroidism associated with 80% recurrence/persistence rate, increasingly difficult re-operations and risk of parathyroid carcinoma (PMID:18436011)
• Parafibromin interacted with muscle alpha-actinins (actinin-2 and actinin-3). (PMID:18687124)
• CDC73 germline mutations are responsible for more than half of cases of hyperparathyroidism-jaw tumor syndrome. (PMID:18755853)
• The parafibromin tumor suppressor protein HRPT2 inhibits cell proliferation by repression of the c-myc proto-oncogene (PMID:18987311)
• Positive staining for PGP9.5 has utility as a marker for parathyroid malignancy, with a slightly superior sensitivity (P = 0.03) and similar high specificity to that of parafibromin. (PMID:19017757)
• A variety of genetic abnormalities, including HRPT2 mutations, occur in parathyroid carcinomas. (PMID:19058032)
• parathyroid carcinoma may be a manifestation of HRPT2 germline mutations (PMID:19081034)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdc73	ENSDARG00000020201
mus_musculus	Cdc73	ENSMUSG00000026361
rattus_norvegicus	Cdc73	ENSRNOG00000003258
drosophila_melanogaster	CG6220	FBGN0033865
caenorhabditis_elegans		WBGENE00018064

Protein

Protein identifiers

Parafibromin — Q6P1J9 (reviewed: Q6P1J9)

Alternative names: Cell division cycle protein 73 homolog, Hyperparathyroidism 2 protein

All UniProt accessions (8): A0A1B0GUB2, A0A2R8Y640, A0A2R8YHB3, A0A3B3IRP5, A0A3B3ISN2, A0AAQ5BGL0, Q6P1J9, A0AAQ5BGL4

UniProt curated annotations — full annotation on UniProt →

Function. Tumor suppressor probably involved in transcriptional and post-transcriptional control pathways. May be involved in cell cycle progression through the regulation of cyclin D1/PRAD1 expression. Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and ‘Ser-2’- and ‘Ser-5’-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 ‘Lys-4’ (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of ‘Lys-120’ of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3’ end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Connects PAF1C with the cleavage and polyadenylation specificity factor (CPSF) complex and the cleavage stimulation factor (CSTF) complex, and with Wnt signaling. Involved in polyadenylation of mRNA precursors.

Subunit / interactions. Component of the PAF1 complex, which consists of CDC73, PAF1, LEO1, CTR9, RTF1 and SKIC8. The PAF1 complex interacts with PHF5A. Within the PAF1 complex interacts directly with PHF5A. Interacts with POLR2A, CPSF1, CPSF4, CSTF2, KMT2A/MLL1 and CTNNB1. Interacts with a Set1-like complex that has histone methyltransferase activity and methylates histone H3. Found in a complex with BCL9L or BCL9, CDC73, CTNNB1 and PYGO1 indicative for the participation in a nuclear Wnt signaling complex. Interacts with PTPN11. Interacts with SETD5. (Microbial infection) The PAF1 complex interacts with Zika virus French Polynesia 10087PF/2013 non-structural protein 5/NS5. The interaction with viral NS5 proteins may reduce the antiviral immune response by inhibiting the recruitment of the PAF1 complex to interferon-stimulated genes, thus preventing their transcription. (Microbial infection) The PAF1 complex interacts with Dengue virus DENV2 16681 non-structural protein 5/NS5. The PAF1 complex interacts with Dengue virus DENV4 Dominica/814669/1981 non-structural protein 5/NS5. The interaction with viral NS5 proteins may reduce the antiviral immune response by inhibiting the recruitment of the PAF1 complex to interferon-stimulated genes, thus preventing their transcription.

Subcellular location. Nucleus.

Tissue specificity. Found in adrenal and parathyroid glands, kidney and heart.

Post-translational modifications. Phosphorylated. Dephosphorylated by PTPN11.

Disease relevance. Hyperparathyroidism 1 (HRPT1) [MIM:145000] An autosomal dominant disorder characterized by hypercalcemia, elevated parathyroid hormone (PTH) levels, and uniglandular or multiglandular parathyroid hyperplasia, adenomas, and carcinomas. The disease is caused by variants affecting the gene represented in this entry. Hyperparathyroidism 2 with jaw tumors (HRPT2) [MIM:145001] An autosomal dominant neoplasia syndrome characterized by primary hyperparathyroidism, ossifying fibroma of the maxilla and/or mandible, renal tumor, and uterine tumors. It is associated with increased risk of parathyroid cancer. The disease is caused by variants affecting the gene represented in this entry. Parathyroid carcinoma (PRTC) [MIM:608266] These cancers characteristically result in more profound clinical manifestations of hyperparathyroidism than do parathyroid adenomas, the most frequent cause of primary hyperparathyroidism. Early en bloc resection of the primary tumor is the only curative treatment. The gene represented in this entry is involved in disease pathogenesis.

Similarity. Belongs to the CDC73 family.

RefSeq proteins (1): NP_078805* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007852	Cdc73/Parafibromin	Family
IPR031336	CDC73_C	Domain
IPR032041	Cdc73_N	Domain
IPR038103	CDC73_C_sf	Homologous_superfamily

Pfam: PF05179, PF16050

UniProt features (42 total): sequence variant 12, helix 7, strand 5, cross-link 4, region of interest 4, sequence conflict 3, modified residue 2, initiator methionine 1, chain 1, turn 1, short sequence motif 1, compositionally biased region 1

Structure

Experimental structures (PDB)

20 structures.

PDB	Method	Resolution (Å)
5YDE	X-RAY DIFFRACTION	1.02
5YDF	X-RAY DIFFRACTION	1.4
9HVQ	ELECTRON MICROSCOPY	2
9MLC	ELECTRON MICROSCOPY	2.4
7OOP	ELECTRON MICROSCOPY	2.9
9EGX	ELECTRON MICROSCOPY	2.9
9EGY	ELECTRON MICROSCOPY	2.9
9EGZ	ELECTRON MICROSCOPY	2.9
7OPC	ELECTRON MICROSCOPY	3
7OPD	ELECTRON MICROSCOPY	3
7UNC	ELECTRON MICROSCOPY	3
7UND	ELECTRON MICROSCOPY	3
6TED	ELECTRON MICROSCOPY	3.1
9EH2	ELECTRON MICROSCOPY	3.1
8A3Y	ELECTRON MICROSCOPY	3.3
9EH0	ELECTRON MICROSCOPY	3.6
9RTT	ELECTRON MICROSCOPY	4.01
9S3G	ELECTRON MICROSCOPY	6.4
9S0U	ELECTRON MICROSCOPY	6.72
9RZE	ELECTRON MICROSCOPY	8.53

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6P1J9-F1	73.94	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 198, 301, 308, 321, 2, 212

Function

Pathways and Gene Ontology

Reactome pathways

17 pathways

ID	Pathway
R-HSA-112382	Formation of RNA Pol II elongation complex
R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex
R-HSA-5632684	Hedgehog ‘on’ state
R-HSA-674695	RNA Polymerase II Pre-transcription Events
R-HSA-75955	RNA Polymerase II Transcription Elongation
R-HSA-8866654	E3 ubiquitin ligases ubiquitinate target proteins
R-HSA-9920588	Dengue virus activates/modulates innate and adaptive immune responses
R-HSA-9943411	CHD1 and CHD2 subfamily
R-HSA-162582	Signal Transduction
R-HSA-195721	Signaling by WNT
R-HSA-201681	TCF dependent signaling in response to WNT
R-HSA-392499	Metabolism of proteins
R-HSA-5358351	Signaling by Hedgehog
R-HSA-597592	Post-translational protein modification
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-8852135	Protein ubiquitination

MSigDB gene sets: 444 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_PROLIFERATION, MORF_ITGA2, PAX4_01, MORF_MSH3, GOBP_CELLULAR_RESPONSE_TO_LIPID, GOBP_FORMATION_OF_PRIMARY_GERM_LAYER, GOBP_POSITIVE_REGULATION_OF_MRNA_PROCESSING, GCANCTGNY_MYOD_Q6, GOBP_CELLULAR_RESPONSE_TO_BIOTIC_STIMULUS, SP3_Q3, MORF_BRCA1, MATTIOLI_MGUS_VS_PCL, GOBP_CELL_CYCLE_PHASE_TRANSITION, GEORGES_CELL_CYCLE_MIR192_TARGETS

GO Biological Process (21): negative regulation of transcription by RNA polymerase II (GO:0000122), regulation of cell growth (GO:0001558), endodermal cell fate commitment (GO:0001711), transcription elongation by RNA polymerase II (GO:0006368), negative regulation of cell population proliferation (GO:0008285), Wnt signaling pathway (GO:0016055), stem cell population maintenance (GO:0019827), positive regulation of Wnt signaling pathway (GO:0030177), mRNA 3’-end processing (GO:0031124), positive regulation of mRNA 3’-end processing (GO:0031442), protein destabilization (GO:0031648), positive regulation of transcription elongation by RNA polymerase II (GO:0032968), negative regulation of apoptotic process (GO:0043066), negative regulation of myeloid cell differentiation (GO:0045638), positive regulation of transcription by RNA polymerase II (GO:0045944), negative regulation of fibroblast proliferation (GO:0048147), negative regulation of epithelial cell proliferation (GO:0050680), cellular response to lipopolysaccharide (GO:0071222), positive regulation of cell cycle G1/S phase transition (GO:1902808), negative regulation of G1/S transition of mitotic cell cycle (GO:2000134), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (2): RNA polymerase II complex binding (GO:0000993), protein binding (GO:0005515)

GO Cellular Component (5): chromosome, telomeric region (GO:0000781), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), Cdc73/Paf1 complex (GO:0016593)

Reactome top-level categories

Rollup of top-12 pathways:

Category	Pathways
RNA Polymerase II Transcription	2
Signal Transduction	2
RNA Polymerase II Transcription Elongation	1
TCF dependent signaling in response to WNT	1
Signaling by Hedgehog	1
Protein ubiquitination	1
Dengue Virus-Host Interactions	1
CHD chromatin remodelers	1
Signaling by WNT	1
Metabolism of proteins	1
Gene expression (Transcription)	1
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transcription by RNA polymerase II	3
regulation of transcription by RNA polymerase II	2
negative regulation of cell population proliferation	2
cellular anatomical structure	2
negative regulation of DNA-templated transcription	1
cell growth	1
regulation of growth	1
regulation of cellular component organization	1
endodermal cell differentiation	1
cell fate commitment involved in formation of primary germ layer	1
DNA-templated transcription elongation	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
cell surface receptor signaling pathway	1
multicellular organismal process	1
maintenance of cell number	1
positive regulation of signal transduction	1
Wnt signaling pathway	1
regulation of Wnt signaling pathway	1
mRNA processing	1
RNA 3’-end processing	1
mRNA 3’-end processing	1
regulation of mRNA 3’-end processing	1
positive regulation of mRNA processing	1
regulation of protein stability	1
transcription elongation by RNA polymerase II	1
positive regulation of DNA-templated transcription, elongation	1
regulation of transcription elongation by RNA polymerase II	1
positive regulation of transcription by RNA polymerase II	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
myeloid cell differentiation	1
negative regulation of cell differentiation	1
regulation of myeloid cell differentiation	1
positive regulation of DNA-templated transcription	1
fibroblast proliferation	1
regulation of fibroblast proliferation	1
epithelial cell proliferation	1

Protein interactions and networks

STRING

3672 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDC73	LEO1	Q8WVC0	999
CDC73	CTR9	Q6PD62	999
CDC73	RTF1	Q92541	997
CDC73	SKIC8	Q9GZS3	996
CDC73	MEN1	O00255	903
CDC73	CTNNB1	P35222	899
CDC73	POLR2A	P24928	884
CDC73	RNF20	Q5VTR2	862
CDC73	CASR	P41180	856
CDC73	GLI1	P08151	841
CDC73	PAF1	Q8N7H5	833
CDC73	RNF40	O75150	824
CDC73	SUPT5H	O00267	801
CDC73	PTH	P01270	752
CDC73	PHF6	Q8IWS0	723

IntAct

364 interactions, top by confidence:

A	B	Type	Score
CCNT1	CDK9	psi-mi:“MI:0914”(association)	0.980
PAF1	CDC73	psi-mi:“MI:0914”(association)	0.960
CDC73	PAF1	psi-mi:“MI:0915”(physical association)	0.960
CDC73	CTR9	psi-mi:“MI:0914”(association)	0.940
CTR9	CDC73	psi-mi:“MI:0914”(association)	0.940
CDC73	CTR9	psi-mi:“MI:0915”(physical association)	0.940
LEO1	CDC73	psi-mi:“MI:0915”(physical association)	0.930
RFX5	RFXAP	psi-mi:“MI:0914”(association)	0.880
GOLGA2	CDC73	psi-mi:“MI:0915”(physical association)	0.850
CEP70	CDC73	psi-mi:“MI:0915”(physical association)	0.850
CDC73	GOLGA2	psi-mi:“MI:0915”(physical association)	0.850

BioGRID (556): CDC73 (Two-hybrid), CDC73 (Two-hybrid), CDC73 (Two-hybrid), CDC73 (Two-hybrid), VPS37B (Two-hybrid), CEP70 (Two-hybrid), TSGA10 (Two-hybrid), FSD2 (Two-hybrid), CCDC155 (Two-hybrid), CDC73 (Affinity Capture-MS), CDC73 (Affinity Capture-MS), CDC73 (Affinity Capture-Western), CDC73 (Affinity Capture-Western), CDC73 (Reconstituted Complex), CTR9 (Affinity Capture-MS)

ESM2 similar proteins: A1CT57, A1DMG9, A1L243, A4R8D7, A5PJG7, C8V9Y5, F1R777, F7VSU2, I1RMK9, I1RX50, O13962, O96005, P06182, P0CM34, P0CM35, P10871, P14187, P25711, P53700, P53701, P53702, P53703, P9WES7, Q00873, Q04499, Q0J6P7, Q0U388, Q13435, Q14696, Q2NL17, Q2UM19, Q4V8C8, Q4WMU5, Q4WN42, Q51LD2, Q552W5, Q5F339, Q5R6F1, Q5U2R7, Q5ZLM0

Diamond homologs: Q4V8C8, Q5ZLM0, Q6P1J9, Q8JZM7, Q9UUE7, Q06697, Q9LJ87

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
CDC73	up-regulates	CTNNB1	binding
CDC73	“form complex”	PAF1C	binding
PTPN11	“up-regulates activity”	CDC73	dephosphorylation
PTK6	“down-regulates activity”	CDC73	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 93 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
HIV elongation arrest and recovery	10	56.7×	7e-14
Pausing and recovery of HIV elongation	10	56.7×	7e-14
Pausing and recovery of Tat-mediated HIV elongation	9	54.4×	2e-12
Tat-mediated HIV elongation arrest and recovery	9	54.4×	2e-12
Signaling by FGFR2 IIIa TM	5	49.3×	8e-07
Abortive elongation of HIV-1 transcript in the absence of Tat	6	48.8×	5e-08
Formation of RNA Pol II elongation complex	14	44.4×	1e-17
RNA Polymerase II Transcription Elongation	14	44.4×	1e-17

GO biological processes:

GO term	Partners	Fold	FDR
transcription elongation by RNA polymerase II	8	46.1×	2e-09
positive regulation of transcription elongation by RNA polymerase II	9	35.2×	2e-09
stem cell population maintenance	5	27.4×	1e-04
transcription by RNA polymerase II	13	11.9×	8e-09

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 1 cancer types — UCEC.

Clinical variants and AI predictions

ClinVar

1986 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	141
Likely pathogenic	31
Uncertain significance	874
Likely benign	794
Benign	30

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1069682	NC_000001.10:g.(?193099298)(193099379_?)del	Pathogenic
1069683	NC_000001.10:g.(?193181185)(193219842_?)del	Pathogenic
1069684	NC_000001.10:g.(?193202113)(193205496_?)del	Pathogenic
1069972	NM_024529.5(CDC73):c.10del (p.Val4fs)	Pathogenic
1072177	NM_024529.5(CDC73):c.341T>A (p.Leu114Ter)	Pathogenic
1074700	NM_024529.5(CDC73):c.415C>T (p.Arg139Ter)	Pathogenic
1075111	NM_024529.5(CDC73):c.878dup (p.Tyr293Ter)	Pathogenic
1076788	NM_024529.5(CDC73):c.687_688del (p.Arg229fs)	Pathogenic
1338411	NM_024529.5(CDC73):c.49del (p.Glu17fs)	Pathogenic
1353959	NM_024529.5(CDC73):c.1012C>T (p.Gln338Ter)	Pathogenic
1355843	NM_024529.5(CDC73):c.628C>T (p.Gln210Ter)	Pathogenic
1388879	NM_024529.5(CDC73):c.1072C>T (p.Arg358Ter)	Pathogenic
1405935	NM_024529.5(CDC73):c.1417dup (p.Ile473fs)	Pathogenic
1414614	NM_024529.5(CDC73):c.893del (p.Phe298fs)	Pathogenic
1452911	NM_024529.5(CDC73):c.201del (p.His68fs)	Pathogenic
1454174	NM_024529.5(CDC73):c.877dup (p.Tyr293fs)	Pathogenic
1454960	NM_024529.5(CDC73):c.501_502del (p.Glu168fs)	Pathogenic
1455290	NM_024529.5(CDC73):c.131+1G>T	Pathogenic
1456469	NM_024529.5(CDC73):c.331del (p.Ser111fs)	Pathogenic
1457823	NM_024529.5(CDC73):c.406A>T (p.Lys136Ter)	Pathogenic
1457824	NM_024529.5(CDC73):c.496C>T (p.Gln166Ter)	Pathogenic
1457825	NM_024529.5(CDC73):c.626_629del (p.Lys209fs)	Pathogenic
1459830	NM_024529.5(CDC73):c.510del (p.Arg171fs)	Pathogenic
1459882	NM_024529.5(CDC73):c.1397del (p.Pro466fs)	Pathogenic
1460166	NC_000001.10:g.(?193104511)(193104729_?)del	Pathogenic
1707836	NM_024529.5(CDC73):c.240del (p.Glu81fs)	Pathogenic
1739774	NM_024529.5(CDC73):c.1171G>T (p.Glu391Ter)	Pathogenic
1740969	NM_024529.5(CDC73):c.449_452del (p.Lys150fs)	Pathogenic
1754215	NM_024529.5(CDC73):c.1226_1230del (p.Lys409fs)	Pathogenic
1765311	NM_024529.5(CDC73):c.897del (p.Gly300fs)	Pathogenic

SpliceAI

3078 predictions. Top by Δscore:

Variant	Effect	Δscore
1:193122327:TGGGG:T	donor_gain	1.0000
1:193122328:GGGG:G	donor_gain	1.0000
1:193122328:GGGGG:G	donor_gain	1.0000
1:193122329:GGG:G	donor_gain	1.0000
1:193122329:GGGG:G	donor_gain	1.0000
1:193122330:GG:G	donor_gain	1.0000
1:193122330:GGG:G	donor_gain	1.0000
1:193122331:GG:G	donor_gain	1.0000
1:193122331:GGTA:G	donor_loss	1.0000
1:193122332:G:GG	donor_gain	1.0000
1:193122332:GT:G	donor_loss	1.0000
1:193122333:T:A	donor_loss	1.0000
1:193125215:GCT:G	donor_gain	1.0000
1:193125217:TG:T	donor_loss	1.0000
1:193125218:G:GA	donor_loss	1.0000
1:193125218:G:GG	donor_gain	1.0000
1:193125219:TAA:T	donor_loss	1.0000
1:193125220:AAGTA:A	donor_loss	1.0000
1:193130161:ATTTT:A	acceptor_gain	1.0000
1:193130165:T:TA	acceptor_gain	1.0000
1:193130166:G:A	acceptor_gain	1.0000
1:193130169:TTTAG:T	acceptor_loss	1.0000
1:193130170:TTA:T	acceptor_loss	1.0000
1:193130171:TAGAC:T	acceptor_loss	1.0000
1:193130172:A:AG	acceptor_gain	1.0000
1:193130172:AGACT:A	acceptor_gain	1.0000
1:193130173:G:GT	acceptor_gain	1.0000
1:193130173:GA:G	acceptor_gain	1.0000
1:193130173:GAC:G	acceptor_gain	1.0000
1:193130173:GACT:G	acceptor_gain	1.0000

AlphaMissense

3460 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:193122214:T:A	L5H	1.000
1:193122223:T:C	L8P	1.000
1:193122294:T:A	W32R	1.000
1:193122294:T:C	W32R	1.000
1:193122318:T:G	Y40D	1.000
1:193125168:T:C	L63P	1.000
1:193125171:T:C	L64P	1.000
1:193125191:C:G	H71D	1.000
1:193125192:A:G	H71R	1.000
1:193125193:T:A	H71Q	1.000
1:193125193:T:G	H71Q	1.000
1:193125200:T:C	Y74H	1.000
1:193125204:T:A	V75D	1.000
1:193125212:G:C	A78P	1.000
1:193130193:T:A	V86D	1.000
1:193130208:G:C	R91P	1.000
1:193130217:T:C	L94P	1.000
1:193130229:T:A	L98H	1.000
1:193130229:T:C	L98P	1.000
1:193141882:T:A	I182N	1.000
1:193141882:T:G	I182S	1.000
1:193141884:G:C	A183P	1.000
1:193141887:G:C	A184P	1.000
1:193141891:T:A	I185N	1.000
1:193141896:G:C	A187P	1.000
1:193147895:T:C	L253P	1.000
1:193150343:T:C	Y290H	1.000
1:193150349:A:G	R292G	1.000
1:193150350:G:C	R292T	1.000
1:193150350:G:T	R292I	1.000

dbSNP variants (sampled 300 via entrez): RS1000009256 (1:193156721 A>G), RS1000075497 (1:193153172 G>C), RS1000106654 (1:193238944 T>G), RS1000118573 (1:193122095 C>G,T), RS1000139394 (1:193192828 C>G,T), RS1000142328 (1:193194769 T>C), RS1000147035 (1:193154731 G>T), RS1000150178 (1:193190238 A>G), RS1000156110 (1:193137203 T>C), RS1000162740 (1:193233766 T>C), RS1000195192 (1:193194545 A>G), RS1000208337 (1:193143796 A>G), RS1000210398 (1:193150917 T>C), RS1000217741 (1:193137526 A>G), RS1000219918 (1:193239343 G>T)

Disease associations

OMIM: gene MIM:607393 | disease phenotypes: MIM:608266, MIM:145000, MIM:145001, MIM:131100, MIM:167000, MIM:114480

GenCC curated gene-disease

Disease	Classification	Inheritance
hyperparathyroidism 2 with jaw tumors	Definitive	Autosomal dominant
parathyroid gland carcinoma	Strong	Autosomal dominant
hyperparathyroidism 1	Strong	Autosomal dominant
familial isolated hyperparathyroidism	Supportive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
hyperparathyroidism 2 with jaw tumors	Definitive	AD

Mondo (11): parathyroid gland carcinoma (MONDO:0012004), hereditary neoplastic syndrome (MONDO:0015356), hyperparathyroidism 1 (MONDO:0007767), hyperparathyroidism 2 with jaw tumors (MONDO:0007768), endocrine gland neoplasm (MONDO:0002082), hyperparathyroidism (MONDO:0001741), multiple endocrine neoplasia type 1 (MONDO:0007540), parathyroid gland adenoma (MONDO:0006890), ovarian cancer (MONDO:0008170), hereditary breast carcinoma (MONDO:0016419), familial isolated hyperparathyroidism (MONDO:0015027)

Orphanet (8): Inherited cancer-predisposing syndrome (Orphanet:140162), Parathyroid carcinoma (Orphanet:143), Familial isolated hyperparathyroidism (Orphanet:99879), Hyperparathyroidism-jaw tumor syndrome (Orphanet:99880), Tumor of endocrine glands (Orphanet:182130), Multiple endocrine neoplasia type 1 (Orphanet:652), Rare ovarian cancer (Orphanet:213500), Hereditary breast cancer (Orphanet:227535)

HPO phenotypes

51 total (30 of 51 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000083	Renal insufficiency
HP:0000107	Renal cyst
HP:0000113	Polycystic kidney dysplasia
HP:0000121	Nephrocalcinosis
HP:0000131	Uterine leiomyoma
HP:0000234	Abnormality of the head
HP:0000787	Nephrolithiasis
HP:0000843	Hyperparathyroidism
HP:0000934	Chondrocalcinosis
HP:0000938	Osteopenia
HP:0000939	Osteoporosis
HP:0001324	Muscle weakness
HP:0001442	Typified by somatic mosaicism
HP:0001609	Hoarse voice
HP:0001733	Pancreatitis
HP:0001824	Weight loss
HP:0001959	Polydipsia
HP:0002015	Dysphagia
HP:0002017	Nausea and vomiting
HP:0002019	Constipation
HP:0002148	Hypophosphatemia
HP:0002150	Hypercalciuria
HP:0002315	Headache
HP:0002574	Episodic abdominal pain
HP:0002653	Bone pain
HP:0002667	Nephroblastoma
HP:0002890	Thyroid carcinoma
HP:0002897	Parathyroid adenoma
HP:0003072	Hypercalcemia

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST001521_27	Subcutaneous adipose tissue	3.000000e-06
GCST003013_35	White matter hyperintensity burden	7.000000e-07
GCST003992_1	Photic sneeze reflex	3.000000e-11
GCST004369_2	Ovarian disease with few adhesions	2.000000e-07
GCST006575_1	Takayasu arteritis	3.000000e-07
GCST007576_230	Chronotype	1.000000e-08
GCST012049_4	High density lipoprotein cholesterol levels	1.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0005665	white matter hyperintensity measurement
EFO:0007887	autosomal dominant compelling helio-ophthalmic outburst syndrome
EFO:0008328	chronotype measurement
EFO:0004612	high density lipoprotein cholesterol measurement

MeSH disease descriptors (6)

Descriptor	Name	Tree numbers
D006961	Hyperparathyroidism	C19.642.355
D018761	Multiple Endocrine Neoplasia Type 1	C04.588.322.400.500; C04.651.600.500; C04.700.630.500; C16.320.700.630.500; C19.344.400.500
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
D010051	Ovarian Neoplasms	C04.588.322.455; C12.050.351.500.056.630.705; C12.050.351.937.418.685; C12.100.250.056.630.705; C12.900.418.685; C19.344.410; C19.391.630.705
C562840	Breast Cancer, Familial (supp.)
C564166	Hyperparathyroidism 1 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724787 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

3 potent at pChembl≥5 of 3 total, top 3 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.19	Kd	64	nM	MOLIBRESIB
7.14	Kd	73	nM	MOLIBRESIB
7.05	IC50	90	nM	MOLIBRESIB

PubChem BioAssay actives

3 with measured affinity, of 8 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2174624: Binding affinity to CDC73 (unknown origin) assessed as apparent dissociation constant	kd	0.0640	uM

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects binding, decreases reaction, affects reaction, increases expression, increases stability (+1 more)	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
TAK-243	increases sumoylation	1
bisphenol A	decreases methylation	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
benzo(e)pyrene	decreases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
benzyloxycarbonylleucyl-leucyl-leucine aldehyde	increases expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
CGP 52608	affects binding, increases reaction	1
abrine	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Arsenic Trioxide	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Endosulfan	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Fluorouracil	decreases expression	1
Ivermectin	decreases expression	1
Methapyrilene	decreases methylation	1
Phenobarbital	affects expression	1
Quercetin	decreases expression	1
Ribonucleotides	affects binding	1
Rotenone	decreases expression	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5696854	Binding	Binding affinity to CDC73 (unknown origin) assessed as apparent dissociation constant	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Cellosaurus cell lines

1 cell lines: 1 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4WZ	MIPTi002-A	Induced pluripotent stem cell	Female

Clinical trials (associated diseases)

187 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00037518	PHASE4	COMPLETED	A Study of an Investigational Medication for Severe Primary Hyperparathyroidism or Parathyroid Cancer
NCT04574947	PHASE4	COMPLETED	Lidocaine And Neuromonitoring in Thyroid Surgery
NCT00359385	PHASE4	WITHDRAWN	The Effects of Alendronate After Cure of Primary Hyperparathyroidism
NCT00379899	PHASE4	COMPLETED	ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
NCT01143987	PHASE4	COMPLETED	Cincalcet and Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism
NCT01573520	PHASE4	COMPLETED	Treatment Adhesion in Dialysis Patients Treated With Cinacalcet
NCT03469310	PHASE4	COMPLETED	Minimizing Narcotic Analgesics After Endocrine Surgery
NCT00190697	PHASE4	COMPLETED	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00727961	PHASE4	COMPLETED	A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)
NCT00740116	PHASE4	COMPLETED	Tranexamic Acid in Surgery of Advanced Ovarian Cancer
NCT00817479	PHASE4	COMPLETED	Tumor Gene Expression in Women With Ovarian Cancer
NCT01432015	PHASE4	COMPLETED	Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
NCT01460030	PHASE3	COMPLETED	An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
NCT03280264	PHASE3	COMPLETED	Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism
NCT00353496	PHASE3	COMPLETED	Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
NCT01964430	PHASE3	COMPLETED	Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the Apact Study)
NCT00417612	PHASE3	COMPLETED	Effectiveness of Paricalcitol in Reducing Parathyroid Hormone (PTH) Levels in X-linked Hypophosphatemic Rickets
NCT00527267	PHASE3	COMPLETED	Safety and Efficacy Study of AMG 073 in Hemodialysis Subjects
NCT00975000	PHASE3	COMPLETED	Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
NCT01191762	PHASE3	COMPLETED	Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease
NCT01277510	PHASE3	TERMINATED	Pediatric Chronic Kidney Disease Safety and Efficacy
NCT04040946	PHASE3	COMPLETED	Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention
NCT03027557	PHASE3	COMPLETED	Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.
NCT00001277	PHASE2	COMPLETED	Studies of Elevated Parathyroid Activity
NCT00896454	PHASE2	COMPLETED	Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT04106843	PHASE2	WITHDRAWN	Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors
NCT00050414	PHASE2	COMPLETED	A Study of Trabectedin in Patients With Advanced Ovarian Cancer
NCT00180960	PHASE2	TERMINATED	Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery and Intraperitoneal Chemohyperthermia
NCT03412877	PHASE2	RECRUITING	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT03562897	PHASE2	COMPLETED	Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
NCT03717298	PHASE2	COMPLETED	Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma
NCT04556071	PHASE2	UNKNOWN	Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
NCT00744302	PHASE2	COMPLETED	Study of 1.25 mmol/L Calcium Dialysate on Mineral Metabolism in Haemodialysis Patients.
NCT01656070	PHASE2	COMPLETED	Vitamin D Supplementation in HIV-infected Youth
NCT02432599	PHASE2	COMPLETED	Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas
NCT00454363	PHASE2	COMPLETED	Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
NCT02101918	PHASE2	COMPLETED	Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery